[{"id":"147008c9-b17e-4123-a459-475c325f46f7","acronym":"T-START-NR","url":"https://clinicaltrials.gov/study/NCT07470996","created_at":"2026-03-28T01:43:49.187Z","updated_at":"2026-03-28T01:43:49.187Z","phase":"","brief_title":"T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR","source_id_and_acronym":"NCT07470996 - T-START-NR","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" ALK negative","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 05/30/2029","primary_completion_date":" 05/30/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"49601ae5-fd50-4ceb-b7f3-e357f9864917","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922724","created_at":"2021-01-18T19:17:55.581Z","updated_at":"2025-02-25T12:27:11.116Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT03922724","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • HLA-B • HLA-C","pipe":" | ","alterations":" ALK positive","tags":["ALK • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • cyclophosphamide • sirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 04/18/2019","start_date":" 04/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-02-24"},{"id":"1a7e9bb9-7b86-4b0f-bf52-ec51de4a9d98","acronym":"P30CA033572","url":"https://clinicaltrials.gov/study/NCT03113500","created_at":"2021-01-18T15:20:28.612Z","updated_at":"2025-02-25T14:01:16.731Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03113500 - P30CA033572","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/25/2017","start_date":" 05/25/2017","primary_txt":" Primary completion: 07/16/2021","primary_completion_date":" 07/16/2021","study_txt":" Completion: 08/12/2025","study_completion_date":" 08/12/2025","last_update_posted":"2025-02-19"},{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"574c26d5-ccf2-4a95-b75d-6e8c523c2e6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02588651","created_at":"2021-01-18T12:33:39.552Z","updated_at":"2025-02-25T14:49:58.459Z","phase":"Phase 2","brief_title":"A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (\u003c10%) Mature T Cell Lymphoma (TCL)","source_id_and_acronym":"NCT02588651","lead_sponsor":"Deepa Jagadeesh","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/17/2016","start_date":" 06/17/2016","primary_txt":" Primary completion: 10/14/2024","primary_completion_date":" 10/14/2024","study_txt":" Completion: 10/14/2024","study_completion_date":" 10/14/2024","last_update_posted":"2025-02-13"},{"id":"a5ee75a6-412a-4439-adb0-ad0586456a5d","acronym":"LCCC1637","url":"https://clinicaltrials.gov/study/NCT03264131","created_at":"2021-01-18T16:07:30.882Z","updated_at":"2025-02-25T15:42:58.677Z","phase":"Phase 2","brief_title":"BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma","source_id_and_acronym":"NCT03264131 - LCCC1637","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 10/11/2018","start_date":" 10/11/2018","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2028","study_completion_date":" 12/15/2028","last_update_posted":"2025-02-10"},{"id":"b0562de4-83b5-474a-a0ea-2bf447d40f13","acronym":"SGN35-032","url":"https://clinicaltrials.gov/study/NCT04569032","created_at":"2021-01-18T21:49:19.024Z","updated_at":"2025-02-25T16:38:04.380Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression","source_id_and_acronym":"NCT04569032 - SGN35-032","lead_sponsor":"Seagen Inc.","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 11/12/2020","start_date":" 11/12/2020","primary_txt":" Primary completion: 05/09/2024","primary_completion_date":" 05/09/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"},{"id":"02fe09dd-fb6d-428c-8c55-0af77e346e1c","acronym":"PTCL13","url":"https://clinicaltrials.gov/study/NCT02223208","created_at":"2025-02-26T10:03:50.822Z","updated_at":"2025-02-26T10:03:50.822Z","phase":"Phase 1/2","brief_title":"Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas","source_id_and_acronym":"NCT02223208 - PTCL13","lead_sponsor":"Fondazione Italiana Linfomi - ETS","biomarkers":" TET2","pipe":" | ","alterations":" TET2 mutation","tags":["TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-12-09"},{"id":"93d233c8-d3b1-4a92-8fd5-b306320c34dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586999","created_at":"2021-01-18T17:38:33.204Z","updated_at":"2025-02-25T14:27:16.447Z","phase":"Phase 1/2","brief_title":"Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas","source_id_and_acronym":"NCT03586999","lead_sponsor":"University of Colorado, Denver","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 05/26/2021","primary_completion_date":" 05/26/2021","study_txt":" Completion: 09/20/2022","study_completion_date":" 09/20/2022","last_update_posted":"2024-10-29"},{"id":"cb1a79b5-e061-4b3c-834a-601d77043b7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512497","created_at":"2021-01-18T12:08:16.611Z","updated_at":"2025-02-25T14:35:44.470Z","phase":"Phase 1","brief_title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT02512497","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • fludarabine IV • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-10-29"},{"id":"7d21338e-ff73-41cf-853f-9516a337a92e","acronym":"FIH","url":"https://clinicaltrials.gov/study/NCT04104776","created_at":"2021-08-13T14:52:51.135Z","updated_at":"2025-02-25T15:43:41.485Z","phase":"Phase 1/2","brief_title":"A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas","source_id_and_acronym":"NCT04104776 - FIH","lead_sponsor":"Constellation Pharmaceuticals","biomarkers":" MSI • ARID1A • BAP1","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["MSI • ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 09/18/2019","start_date":" 09/18/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-08-02"},{"id":"b4d402cb-9b95-4ade-8b2a-ba008e6e8258","acronym":"","url":"https://clinicaltrials.gov/study/NCT04234048","created_at":"2021-01-18T20:35:42.430Z","updated_at":"2024-07-02T16:34:26.824Z","phase":"Phase 1","brief_title":"Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04234048","lead_sponsor":"SciTech Development, LLC","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fenretinide nanoparticle (ST-001 nanoFenretinide)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-06-12"},{"id":"5dee7c2d-c458-4efc-8ddb-50ee403de9bf","acronym":"SGN35-015","url":"https://clinicaltrials.gov/study/NCT01716806","created_at":"2021-01-18T07:28:55.529Z","updated_at":"2024-07-02T16:34:27.249Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT01716806 - SGN35-015","lead_sponsor":"Seagen Inc.","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • dacarbazine • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 10/31/2012","start_date":" 10/31/2012","primary_txt":" Primary completion: 04/07/2023","primary_completion_date":" 04/07/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2024-06-11"},{"id":"9cceceb2-4e58-41ef-ba8e-6eddd7740571","acronym":"","url":"https://clinicaltrials.gov/study/NCT05371054","created_at":"2022-05-12T15:56:31.055Z","updated_at":"2024-07-02T16:34:37.584Z","phase":"Phase 1/2","brief_title":"Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies","source_id_and_acronym":"NCT05371054","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • BCL2","pipe":" | ","alterations":" MYC rearrangement","tags":["ALK • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • prednisone • enitociclib (VIP152)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 03/10/2025","primary_completion_date":" 03/10/2025","study_txt":" Completion: 03/10/2025","study_completion_date":" 03/10/2025","last_update_posted":"2024-06-06"},{"id":"144749df-0a66-4aa2-9a78-56b647da62a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05313243","created_at":"2022-04-06T14:52:59.872Z","updated_at":"2025-02-25T16:17:33.219Z","phase":"Phase 2","brief_title":"Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma","source_id_and_acronym":"NCT05313243","lead_sponsor":"Yale University","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2024-06-05"},{"id":"b8d254b3-f15e-4c07-822c-72a282b1d8ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT06120504","created_at":"2023-11-07T16:14:29.912Z","updated_at":"2024-07-02T16:35:00.615Z","phase":"Phase 1","brief_title":"A Safety Study of SGN-35T in Adults With Advanced Cancers","source_id_and_acronym":"NCT06120504","lead_sponsor":"Seagen Inc.","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2024-05-28"},{"id":"531ae39e-01c4-436e-9a46-eb2502847532","acronym":"LuminICE-203","url":"https://clinicaltrials.gov/study/NCT05883449","created_at":"2023-06-01T14:07:49.446Z","updated_at":"2024-07-02T16:35:00.909Z","phase":"Phase 2","brief_title":"Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL","source_id_and_acronym":"NCT05883449 - LuminICE-203","lead_sponsor":"Affimed GmbH","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-05-27"},{"id":"88d90e77-172d-4510-b158-f4795d53f576","acronym":"CRESCENDO","url":"https://clinicaltrials.gov/study/NCT06072131","created_at":"2023-10-10T15:12:06.102Z","updated_at":"2024-07-02T16:35:00.782Z","phase":"Phase 3","brief_title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","source_id_and_acronym":"NCT06072131 - CRESCENDO","lead_sponsor":"Acrotech Biopharma Inc.","biomarkers":" ALK • TNFRSF8 • UGT1A1","pipe":" | ","alterations":" TNFRSF8 expression • UGT1A1*1*1","tags":["ALK • TNFRSF8 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Beleodaq (belinostat) • Folotyn (pralatrexate)"],"overall_status":"Recruiting","enrollment":" Enrollment 504","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 11/01/2030","study_completion_date":" 11/01/2030","last_update_posted":"2024-05-27"},{"id":"e704c4fd-c7ac-4597-8954-effccdbd050f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949944","created_at":"2023-07-20T15:09:21.771Z","updated_at":"2024-07-02T16:35:02.840Z","phase":"Phase 1/2","brief_title":"Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT05949944","lead_sponsor":"Sun Yat-sen University","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 expression • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 expression • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Itari (linperlisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-17"},{"id":"d18b18cb-b903-4ed3-9008-7bb395a62471","acronym":"","url":"https://clinicaltrials.gov/study/NCT03297697","created_at":"2021-01-18T16:17:32.348Z","updated_at":"2024-07-02T16:35:03.192Z","phase":"","brief_title":"Minimal Residual Disease in Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03297697","lead_sponsor":"Washington University School of Medicine","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2024-05-16"},{"id":"a42b730f-7cb0-4a7e-b9c9-5253a2b3eeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04390737","created_at":"2022-05-12T19:53:40.351Z","updated_at":"2024-07-02T16:35:04.605Z","phase":"Phase 1/2","brief_title":"Evaluate the Safety and Clinical Activity of HH2853","source_id_and_acronym":"NCT04390737","lead_sponsor":"Haihe Biopharma Co., Ltd.","biomarkers":" ARID1A • BAP1","pipe":" | ","alterations":" ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation","tags":["ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HH2853"],"overall_status":"Recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-09"},{"id":"25e24245-9e4c-4767-b5e7-b2e9ba8446f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983965","created_at":"2023-08-09T14:09:35.762Z","updated_at":"2024-07-02T16:35:05.238Z","phase":"Phase 1","brief_title":"Study of Tazemetostat in Lymphoid Malignancies","source_id_and_acronym":"NCT05983965","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CD4","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Tazverik (tazemetostat)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-08"},{"id":"0fe10839-16f3-4ebf-97c8-7feb7f85fc90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083208","created_at":"2021-10-19T15:58:00.734Z","updated_at":"2024-07-02T16:35:05.553Z","phase":"Phase 1/2","brief_title":"PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT05083208","lead_sponsor":"Henan Cancer Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide) • parsaclisib (INCB50465)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 02/20/2022","start_date":" 02/20/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-07"}]